Evolysse™ Recognized in 2025 Shape Skin Awards
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin Awards:
- Evolysse™ Recognized as the Best Filler for 2025 with its recently launched injectable hyaluronic acid gel line
- Best Membership Treatment Model for Club Evolus™, its proprietary consumer rewards program
The annual Shape Skin Awards highlight innovation and performance across the skincare and aesthetics industry. This year the judging panel of board-certified dermatologists and specialists evaluated more than 800 products and treatments, ultimately selecting winners across a range of categories.
"To be recognized in the 2025 Shape Skin Awards just weeks after the launch of Evolysse™ highlights the uniqueness of the COLD-X™ technology," said David Moatazedi, President and Chief Executive Officer at Evolus. "This recognition reflects how well-positioned we are to compete in the injectable HA category and supports our broader strategy of building a differentiated aesthetic platform designed for sustained growth."
Evolysse™ Form and Evolysse™ Smooth, the first two products in the Evolysse™ line, were approved by the FDA in February 2025 and launched in the U.S. in April. The collection utilizes innovative Cold-X™ technology that is intended to preserve the natural structure of the hyaluronic acid (HA) molecule for long-lasting and natural-looking results.
In addition to product innovation, Evolus' commercial model was recognized for its consumer engagement strategy through Club Evolus™, the company's digital loyalty platform. Club Evolus™ is designed to drive repeat visits, support cash-pay practices, and elevate the aesthetic treatment experience through a personalized, rewards-based model.
Together, these two awards reflect Evolus' unique positioning at the intersection of science, brand and consumer accessibility, delivering both performance and experience in the self-pay aesthetics market.
About Evolus, Inc.
Evolus (NASDAQ:EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
EVOLYSSE™ Uses and Important Safety Information
Approved Uses
EVOLYSSE™ SMOOTH and EVOLYSSE™ FORM are injected into the skin to smooth wrinkles that form in dynamic areas of the face, especially between the nose and corners of the mouth (NLFs), in adults 22 and older.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive treatment with EVOLYSSE injectable hyaluronic acid products?
Do not use EVOLYSSE™ products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), or if you are allergic to lidocaine or Gram-positive bacterial proteins.
What precautions should my doctor advise me about?
- Minimize exposure to extreme heat or cold as doing so may cause temporary redness, swelling, and/or itching at the injection site.
- Tell your doctor if you are using medication that can prolong bleeding, such as aspirin, ibuprofen, or other blood thinners, as this may increase bruising or bleeding at the injection site.
- Tell your doctor if you are planning laser treatment, chemical peel, or any other procedure after treatment as there is a possible risk of an inflammatory reaction at the treatment site.
- EVOLYSSE™ products are intended for dynamic wrinkles and folds such as NLFs. The safety and effectiveness for other treatment areas have not been established.
- Tell your doctor if you are on therapy used to decrease your immune response, which can increase risk of infection with treatment.
- Tell your doctor if you are pregnant or breastfeeding. The safety for use during pregnancy or in women who are breastfeeding has not been studied.
- Tell your doctor if you have a history of excessive scarring (thick, hard scars) or pigmentation disorders, as use of these products may result in additional scars or changes in pigmentation.
- Tell your doctor if you have a history of cold sores. Any injections, including EVOLYSSE™ products, around the mouth may trigger a recurrence of your cold sores.
- The use of EVOLYSSE™ products where skin sores, pimples, rashes, hives, cysts, or infections are present should be postponed until healing is complete. Use of EVOLYSSE™ products where these are present could delay healing or make your skin problems worse.
What are the possible side effects of treatment?
The most commonly reported side effects with EVOLYSSE™ products were tenderness, swelling, bruising, redness, lumps, pain, discoloration, itching, and headache. Most side effects were mild and went away on their own within 1 week.
What are other possible adverse events?
As with all skin injection procedures, there is a risk of infection. One of the risks with using these products is unintentional injection into a blood vessel. Although the chances of this happening are very small, complications can be serious and may be permanent, and include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. If you have changes in your vision, signs of a stroke (including sudden difficulty speaking, numbness or weakness in your face, arms, or legs, difficulty walking, face drooping, severe headache, dizziness, or confusion), white appearance of the skin, or unusual pain during or shortly after treatment, you should call your doctor immediately. To report a side effect with any EVOLYSSE™ product, please call Evolus Customer Experience at 1-877-386-5871.
EVOLYSSE™ products are available only by a licensed physician or properly licensed practitioner.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
Cold-X™ is a trademark of Symatese Group and Symatese Aesthetics S.A.S.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610917045/en/
Investor Contact:
Email: [email protected]
Media Contact:
Email: [email protected]